Molecular Imaging and Therapy for Neuroendocrine Tumors

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical therapy

Background:

• Neuroendocrine tumors (NETs) are rare neoplasms with specific molecular targets.
• Traditional imaging used SPECT with ¹¹¹In-octreotide and ¹²³I/¹³¹I-MIBG.
• Emerging PET imaging offers higher sensitivity for NET detection.

Purpose of the Study:

• To provide an overview of current nuclear medicine imaging and therapy for NETs.
• To highlight the role of metaiodobenzylguanidine (MIBG) and somatostatin receptor (SSR) probes.
• To discuss the theranostic potential of paired diagnostic/therapeutic agents.

Main Methods:

• Review of SPECT imaging using ¹¹¹In-octreotide analogs.
• Review of MIBG imaging (¹²³I/¹³¹I) for specific NET types.
• Discussion of advanced PET imaging with ⁶⁸Ga-labeled SSR analogs (e.g., ⁶⁸Ga-DOTATATE).

Main Results:

• ⁶⁸Ga-DOTATATE (FDA approved 2016) significantly enhances PET imaging sensitivity for NETs.
• Therapeutic applications include high-dose ¹³¹I-MIBG and ¹⁷⁷Lu-DOTATATE (FDA approved 2018 for gastroenteropancreatic NETs).
• The theranostic approach enables precise targeting and delivery of radiation to tumor sites.

Conclusions:

• MIBG and SSR-based radiopharmaceuticals are crucial for NET diagnosis and therapy.
• The theranostic paradigm represents a major advancement in managing NETs.
• Knowledge gained from NETs serves as a model for developing similar probes for other cancers.